MedGenome is a genomics and clinical data driven genetic testing and drug discovery research company and a leader in genetic testing with expertise in identifying genetic mutations using simultaneous genome sequencing and clinical data analysis.
With the state-of-the-art Next Generation Sequencing (NGS) facility, MedGenome is one of the highest throughput NGS & CAP accredited lab in South Asia. MedGenome offers comprehensive diagnostic solutions to researchers, doctors and hospitals.
Centogene is one of the largest genetic biotech companies worldwide, the European market leader, and one of the global leaders in genetic diagnostic analyses of rare inherited diseases.
Centogene is focused on transforming clinical, genetic, and biochemical data into medical solutions for patients with a global network of partners.
Click here to learn more about Centogene’s diagnostic services.
We joined hands with MediLinks to provide Oncotype DX to Sri Lankans. The Oncotype DX test is a genomic test that analyzes the activity of a group of genes that can affect how a cancer is likely to behave and respond to treatment. The Oncotype DX is used in two ways:
Of all the breast cancer genomic tests, the Oncotype DX test has the strongest research behind it.
FoundationOne CDx is a broad companion diagnostic (CDx) that is clinically and analytically validated for solid tumors including: NSCLC, Colorectal, Breast, Ovarian, and Melanoma. The test is designed to provide physicians with clinically actionable information.
To consider appropriate therapies for patients and understand results with evidence of resistance. Based on the individual genomic profile of each patience’s cancer.
Every test result includes microsatellite instability (MSI) and tumor mutational burden (TMB) to help inform immunotherapy decisions.
Click here to learn more about FoundationOne CDx genomic test.
A single test that analyzes all guideline-recommended genes in solid tumors, including companion diagnostic indications with a direct path to therapy.
Results include MSI and TMB with the option to add PD-L1 testing to help inform immunotherapy decisions.
CanAssist-Breast test helps clinicians formulate personalized therapeutic programs for their patients. The result is precision medicine that could shorten recovery time and improve the patients’ quality of life.
CanAssist-Breast test provides additional information about the cancerous tumor. Along with the existing pathology report, this test result can help identify the likelihood of the cancer returning post-surgery and whether the patient is likely to benefit from adding chemotherapy to her hormone therapy.
Contact us to arrange a testIndia’s Largest Cancer Diagnostic Network with over 18 years of experience under its belt, College of American Pathology (CAP) and NABL accredited laboratory, Oncquest is known for its excellence in Molecular and Clinical Diagnostics.
4baseCare is a precision oncology company leveraging advanced genomic technologies to provide personalized cancer care.
4BaseCare performs the DNA and RNA sequencing to generate high-quality somatic and germline molecular data. The results empower physicians to make data-driven personalized treatment decisions.
4BaseCare’s target portfolio tests are validated to identify somatic mutations in the tumour tissue with high sensitivity and specificity to detect even low frequency genomic alterations.
The hereditary Cancer Risk test – Germline+ allows one to identify specific variations in the genes which are known to be associated with cancer.